Comparative Pharmacology
Head-to-head clinical analysis: CERVIDIL versus DINOPROSTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERVIDIL versus DINOPROSTONE.
CERVIDIL vs Dinoprostone
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaglandin E2 (PGE2) receptor agonist; induces cervical ripening and uterine contractions via binding to EP receptors, increasing intracellular calcium and promoting gap junction formation.
Prostaglandin E2 (PGE2) agonist; stimulates uterine smooth muscle contractions, promotes cervical ripening by increasing collagenase activity and softening connective tissue, and induces gap junction formation between myometrial cells.
10 mg vaginal insert (dinoprostone) placed high in the posterior vaginal fornix; may be removed after 12 hours or onset of active labor; one insert per 24 hours.
Cervical ripening: 0.5 mg dinoprostone gel (Prepidil) intracervically every 6 hours as needed, max 3 doses in 24 hours; or 10 mg vaginal insert (Cervidil) placed transversely in posterior vaginal fornix, removed after 12 hours or at onset of active labor. Termination of pregnancy: 20 mg vaginal suppository (Prostin E2) every 3-5 hours until abortion, max 240 mg total.
None Documented
None Documented
Clinical Note
moderateDinoprostone + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dinoprostone."
Clinical Note
moderateTiaprofenic acid + Dinoprostone
Terminal elimination half-life of dinoprostone is 2.5 to 5 minutes; clinical effects persist due to sustained release formulation (e.g., vaginal insert).
Terminal elimination half-life is 2.5-5 minutes due to rapid metabolism in the lungs; clinical effects persist longer due to tissue binding.
Primarily hepatic metabolism via 15-hydroxyprostaglandin dehydrogenase; metabolites are excreted renally (approximately 60% over 24 hours) and fecally (approximately 40%).
Approximately 90% metabolized in the lung, liver, and kidney; metabolites excreted in urine (primary) and feces. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Prostaglandin
Prostaglandin
"The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid."